自身免疫性脑炎49例的预后分析

摘要
图/表
参考文献(28)
相关文章 (15)

全文: PDF (575 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的分析自身免疫性脑炎的症状学特征及神经功能恢复情况，探索影响患者预后的相关因素。方法回顾性研究2013年1月~2017年2月于重庆医科大学附属第一医院确诊为自身免疫性脑炎的49例患者，进行临床资料收集并随访，使用改良Ranking量表（mRS）评估患者神经功能恢复情况，将患者分为痊愈组（mRS评分0~1分，32例），部分恢复组（mRS评分2~3分，7例）及预后不佳组（mRS评分＞3分，10例）。采用有序多分类逻辑回归统计学分析方法对预后进行分析。结果 79.59％的患者获得痊愈或部分恢复。精神行为异常的完全恢复率为75.61％，癫痫发作的完全恢复率为94.29％，近事记忆力障碍完全恢复率为69.57％，不自主运动的完全恢复率为87.50％，中枢神经系统局灶性损害的完全恢复率为90.63％，16.33％的患者出现复发。三组患者首次发病的病前异常免疫状态、伴有自主神经功能障碍或中枢性低通气、单独采用激素治疗者占比比较，差异均有统计学意义（P < 0.05）。病前处于异常免疫状态以及首次发病伴有自主神经功能障碍或中枢性低通气症状是自身免疫性脑炎患者预后不良的独立预测因素（P < 0.05）。结论多数自身免疫性脑炎患者预后较好，部分遗留精神行为异常、记忆力下降；首次发病前处于异常免疫状态，伴有明显的自主神经功能障碍或中枢性低通气可能提示预后不佳；免疫治疗可改善患者预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	郭同利1 李光勤1 孙金辉2 罗业涛3

关键词 ：自身免疫性脑炎, 临床特征, 预后

Abstract：Objective To analyze the features of clinical symptoms, neurological functional recovery and the prognostic factors of autoimmune encephalitis. Methods A retrospective study of 49 patients diagnosed with autoimmune encephalitis in the First Affiliated Hospital of Chongqing Medical University from January 2013 to February 2017 was performed. Clinical data were collected and followed up. The neurological functional recovery was evaluated through modified ranking scale (mRS). The patients were divided into the recovery group (mRS score 0-1, 32 cases), partial recovery group (mRS score 2-3 scores, 7 cases), and poor prognosis group (mRS score > 3 scores, 10 cases), and the prognostic factors were analyzed using statistical methods of Logistic regression analysis of ordered categorization. Results 79.59％ patients were completely recovered or remained mild neurological dysfunction. 75.61％ of the mental and behavior disorders were fully recovered, 94.29% of the seizures were controlled, 69.57％ of the recent memory disorders were completely recovered, 87.50％ of the inadvertent movement were controlled, 90.63％ of the central nervous system focal damage were fully recovered and 16.33％ of the patients relapsed. Comparison of clinical data of initial onset among the three groups showed that people in abnormal immune status before onset and initial clinical manifestation with autonomic dysfunction or central hypoventilation had statistically significant difference(P < 0.05). Abnormal immune status before the disease and the first onset accompanied by autonomic nervous dysfunction or central hypoventilation are independent predictors of poor prognosis in patients with autoimmune encephalitis (P < 0.05). Conclusion The majority of autoimmune encephalitis patients have favorable prognosis, but some of the patients may remain various degrees of neurological deficiency, including mental and behavior disorders and recent memory disorders. People in abnormal immune status before the onset and initial clinical manifestation with autonomic dysfunction or central hypoventilation may indicate a poorer prognosis． Immunotherapy can improve outcomes.

Key words： Autoimmune encephalitis Clinical features Prognosis

通讯作者: 李光勤（1965.6-），男，神经病学博士，主任医师，教授，硕士生导师；研究方向：颅内感染、脑血管病等的诊断和治疗。

作者简介: 郭同利（1993.4-），女，重庆医科大学2015级神经病学专业在读硕士研究生；研究方向：颅内感染、脑血管病等。

引用本文:

郭同利1 李光勤1 孙金辉2 罗业涛3. 自身免疫性脑炎49例的预后分析[J]. 中国医药导报, 2018, 15(23): 62-66.
GUO Tongli1 LI Guangqin1 SUN Jinhui2 LUO Yetao3. Prognosis analysis of 49 cases with autoimmune encephalitis. 中国医药导报, 2018, 15(23): 62-66.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2018/V15/I23/62

[1] Guan HZ，Ren HT，Cui LY. Autoimmune Encephalitis： An Expanding Frontier of Neuroimmunology[J]. Chin Med J (Engl)，2016，129（9）：1122-1127.
[2] 中华医学会神经病学分会.中国自身免疫性脑炎诊治专家共识[J].中华神经科杂志，2017，50（2）：91-98.
[3] Graus F，Titulaer MJ，Balu R，et al. A clinical approach to diagnosis of autoimmune encephalitis [J]. Lancet Neurol，2016，15（4）：391-404.
[4] Titulaer MJ，Mccracken L，Gabilondo I，et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis： an observational cohort study [J]. Lancet Neurol，2013，12（2）：157-165.
[5] Banks JL，Marotta CA. Outcomes validity and reliability of the modified Rankin scale： implications for stroke clinical trials：a literature review and synthesis [J]. Stroke，2007， 38（3）：1091-1096.
[6] Dalmau J，Lancaster E，Martinezhernandez E，et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis [J]. Lancet Neurol，2011， 10（1）：63-74.
[7] Wang W，Li JM，Hu FY，et al. Anti-NMDA receptor encephalitis： clinical characteristics， predictors of outcome and the knowledge gap in southwest China [J]. Eur J Neurol，2016，23（3）：621-629.
[8] Dalmau J，Gleichman AJ，Hughes EG，et al. Anti-NMDA．receptor encephalitis：ease series and analysis of the effects of antibodies [J]. Lancet Neurol，2008，7（12）：1091-1098.
[9] 徐文灯，贺菲菲，叶静.抗N-甲基-D-天冬氨酸受体脑炎51例的预后分析[J].中华神经科杂志，2017，50（2）：99-102.
[10] Mariotto S，Tamburin S，Salviati A，et al. Anti-N-methyl-d-aspartate receptor encephalitis causing a prolonged depressive disorder evolving to inflammatory brain disease [J]. Case Rep Neurol，2014，6（1）：38-43.
[11] Ngugi AK，Kariuki SM，Bottomley C，et al. Incidence of epilepsy：a systematic review and meta-analysis [J]. Neurology，2011，77（10）：1005-1012.
[12] Kamei S，Kuzuhara S，Ishihara M，et al. Nationwide survey of acute juvenile female non-herpetic encephalitis in Japan： relationship to anti-N-methyl-D-aspartate receptor encephalitis [J]. Internal Med，2009，48（9）：673-679.
[13] Titulaer MJ，Mccracken L，Gabilondo I，et al. Late-onset anti-NMDA receptor encephalitis [J]. Neurology，2013， 81（12）：1058-1063.
[14] Lim JA，Lee ST，Jung KH，et al. Anti-N-methyl-d-aspartate receptor encephalitis in Korea： clinical features， treatment， and outcome [J]. J Clin Neurol，2014，10（2）：157-161.
[15] Chi X，Wang W，Huang C，et al. Risk factors for mortality in patients with anti-NMDA receptor encephalitis [J]. Acta Neurol Scand，2017，136（4）：298-304.
[16] Vitaliani R，Mason W，Ances B，et al. Paraneoplastic encephalitis, psychiatric symptoms， and hypoventilation in ovarian teratoma [J]. Ann Neurol，2005，58（4）：594-604.
[17] Dalmau J，Lancaster E，Martinez-Hernandez E，et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis [J]. Lancet Neurol，2011， 10（1）：63-74.
[18] Day GS，High SM，Cot B，et al. Anti-NMDA-receptor encephalitis：case report and literature review of an under-recognized condition [J]. Gen Intern Med，2011，26（7）：811-816.
[19] Hughes EG，Peng X，Gleichman AJ，et al. Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis [J]. J Neurosci，2010，30（17）：5866-5875.
[20] Bien CG，Vincent A，Barnett MH，et al. Immunopathology of autoantibody-associated encephalitides：clues for patho-genesis [J]. Brain，2012，135（5）：1622-1638.
[21] Moscato EH，Peng X，Jain A，et al. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis [J]. Ann Neurol，2014，76（1）：108-119.
[22] Kamei S，Kuzuhara S，Ishihara M，et al. Nationwide survey of acute juvenile female non-herpetic encephalitis in Japan： relationship to anti-N-methyl-D-aspartate receptor encephalitis [J]. Internal Med，2009，48（9）：673-679.
[23] Irani SR，Bera K，Waters P，et al. N-methyl-d-aspartate antibody encephalitis： temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes [J]. Brain，2010，133（6）：1655-1667.
[24] 孔文龙，石小峰，纠智松，等.脑损伤急性期水电解质紊乱及神经内分泌功能障碍的临床研究[J].现代医院，2018，18（4）：596-598，601.
[25] 李上华，吴学永，黎才源.阿托伐他汀对腔隙性脑梗死合并CMBs患者神经功能及认知功能的影响[J].中国医学创新，2018，15（17）：43-46.
[26] Byrne S，Walsh C，Hacohen Y，et al. Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome [J]. Neuroimmunol Neuroinflamm，2015，2（4）：e130.
[27] Ances BM，Vitaliani R，Taylor RA，et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies： MRI and PET correlates [J]. Brain，2005，128（8）：1764-1777.
[28] Dale RC，Brilot F，Duffy LV，et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease [J]. Neurology，2014，83（2）：142-150.